



Vascular Pathologies in the Omics-Era

Guest Editor:

Dr. Deepti Diwan

Washington University School of
Medicine, Saint Louis, MO 63110,
USA

Deadline for manuscript
submissions:

31 January 2025

Message from the Guest Editor

Vascular pathology encompasses a spectrum of conditions impacting blood vessels and represents a pivotal area of inquiry within the burgeoning discipline of omics. This field involves a comprehensive analysis of diverse biomolecules on a large scale. In this omics era, researchers harness advanced technologies, including genomics, transcriptomics, proteomics, and metabolomics, in order to gain deeper insights into the intricate molecular mechanisms underlying vascular pathology. By scrutinizing the omics approaches of individuals with vascular ailments, researchers can pinpoint potential biomarkers for early detection, devise targeted therapeutic interventions, and enhance patient outcomes. The amalgamation of omics methodologies has yielded novel perspectives on the pathogenesis of vascular pathology and has forged a path toward tailored medical strategies to address these maladies. At its core, leveraging omics in exploring vascular pathology is anticipated to catalyze advancements in our comprehension and management of these intricate health challenges. This Special Issue invites original research and comprehensive reviews on the intersection of vascular diseases and omics.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)